Reduction of the Deleterious Effects of Tobacco Smoking by the Induction of Phase 2 Enzymes by Nerf2
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- SAVIPU PHARMA
- Publication Date
- 2008-01-24
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] This application claims priority of U.S. Application Ser. No. 60 / 807,685 filed on Jul. 18, 2006 and incorporated herein in its entirety by reference.Background of the Invention
[0002] 1. Field of the Invention
[0003] The field of the invention relates to the treatment of tobacco to lessen the deleterious effect of tobacco smoking. In particular the invention relates to the treatment of tobacco or a tobacco product with an effective amount of an inhibitor of oxidative stress due to the induction of phase 2 enzymes regulated by Nerf2 such that the deleterious effects of smoking tobacco are reduced.
[0004] 2. Description of the Related Art
[0005] Tobacco smoke (TS) is a major risk factor for a number of diseases including cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease. Smokers have a high incidence of lung cancer, which is the most common cause of cancer in Western countries, accounting for more deaths than those caused by prostrate, breast, and ...